vs

Side-by-side financial comparison of IDACORP INC (IDA) and LivaNova PLC (LIVN). Click either name above to swap in a different company.

LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $360.1M, roughly 1.0× IDACORP INC). IDACORP INC runs the higher net margin — 12.1% vs 8.6%, a 3.5% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -4.2%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $-216.2M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -7.2%).

IDACORP, Inc is an electricity holding company, incorporated in Idaho with headquarters in Boise. It comprises Idaho Power Company, IDACORP Financial and Ida-West Energy. It was formed on October 1, 1998.

LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".

IDA vs LIVN — Head-to-Head

Bigger by revenue
LIVN
LIVN
1.0× larger
LIVN
$360.9M
$360.1M
IDA
Growing faster (revenue YoY)
LIVN
LIVN
+16.3% gap
LIVN
12.1%
-4.2%
IDA
Higher net margin
IDA
IDA
3.5% more per $
IDA
12.1%
8.6%
LIVN
More free cash flow
LIVN
LIVN
$266.4M more FCF
LIVN
$50.2M
$-216.2M
IDA
Faster 2-yr revenue CAGR
LIVN
LIVN
Annualised
LIVN
10.6%
-7.2%
IDA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IDA
IDA
LIVN
LIVN
Revenue
$360.1M
$360.9M
Net Profit
$43.6M
$30.9M
Gross Margin
65.2%
Operating Margin
14.9%
11.8%
Net Margin
12.1%
8.6%
Revenue YoY
-4.2%
12.1%
Net Profit YoY
15.1%
-44.7%
EPS (diluted)
$0.78
$0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDA
IDA
LIVN
LIVN
Q4 25
$360.1M
$360.9M
Q3 25
$526.4M
$357.8M
Q2 25
$449.3M
$352.5M
Q1 25
$411.1M
$316.9M
Q4 24
$375.9M
$321.8M
Q3 24
$532.5M
$318.1M
Q2 24
$442.6M
$318.6M
Q1 24
$417.9M
$294.9M
Net Profit
IDA
IDA
LIVN
LIVN
Q4 25
$43.6M
$30.9M
Q3 25
$124.4M
$26.8M
Q2 25
$95.8M
$27.2M
Q1 25
$59.6M
$-327.3M
Q4 24
$37.9M
$55.9M
Q3 24
$113.6M
$33.0M
Q2 24
$89.5M
$16.3M
Q1 24
$48.2M
$-41.9M
Gross Margin
IDA
IDA
LIVN
LIVN
Q4 25
65.2%
Q3 25
68.4%
Q2 25
67.8%
Q1 25
69.7%
Q4 24
68.2%
Q3 24
70.8%
Q2 24
68.7%
Q1 24
70.3%
Operating Margin
IDA
IDA
LIVN
LIVN
Q4 25
14.9%
11.8%
Q3 25
27.5%
15.1%
Q2 25
22.4%
15.4%
Q1 25
13.4%
15.3%
Q4 24
11.0%
11.5%
Q3 24
25.1%
11.2%
Q2 24
23.3%
12.6%
Q1 24
11.9%
5.5%
Net Margin
IDA
IDA
LIVN
LIVN
Q4 25
12.1%
8.6%
Q3 25
23.6%
7.5%
Q2 25
21.3%
7.7%
Q1 25
14.5%
-103.3%
Q4 24
10.1%
17.4%
Q3 24
21.3%
10.4%
Q2 24
20.2%
5.1%
Q1 24
11.5%
-14.2%
EPS (diluted)
IDA
IDA
LIVN
LIVN
Q4 25
$0.78
$0.57
Q3 25
$2.26
$0.49
Q2 25
$1.76
$0.50
Q1 25
$1.10
$-6.01
Q4 24
$0.72
$1.04
Q3 24
$2.12
$0.60
Q2 24
$1.71
$0.30
Q1 24
$0.95
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDA
IDA
LIVN
LIVN
Cash + ST InvestmentsLiquidity on hand
$215.7M
$635.6M
Total DebtLower is stronger
$3.3B
$376.1M
Stockholders' EquityBook value
$3.6B
$1.2B
Total Assets
$10.2B
$2.6B
Debt / EquityLower = less leverage
0.93×
0.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDA
IDA
LIVN
LIVN
Q4 25
$215.7M
$635.6M
Q3 25
$333.2M
$646.1M
Q2 25
$474.5M
$593.6M
Q1 25
$634.5M
$738.4M
Q4 24
$368.9M
$428.9M
Q3 24
$427.9M
$346.4M
Q2 24
$169.6M
$329.2M
Q1 24
$157.6M
$309.2M
Total Debt
IDA
IDA
LIVN
LIVN
Q4 25
$3.3B
$376.1M
Q3 25
$434.5M
Q2 25
$430.6M
Q1 25
$628.2M
Q4 24
$3.1B
$627.0M
Q3 24
$625.5M
Q2 24
$624.5M
Q1 24
$623.8M
Stockholders' Equity
IDA
IDA
LIVN
LIVN
Q4 25
$3.6B
$1.2B
Q3 25
$3.5B
$1.2B
Q2 25
$3.4B
$1.1B
Q1 25
$3.3B
$1.0B
Q4 24
$3.3B
$1.3B
Q3 24
$3.3B
$1.3B
Q2 24
$3.2B
$1.2B
Q1 24
$2.9B
$1.2B
Total Assets
IDA
IDA
LIVN
LIVN
Q4 25
$10.2B
$2.6B
Q3 25
$10.1B
$2.6B
Q2 25
$9.9B
$2.5B
Q1 25
$9.6B
$2.6B
Q4 24
$9.2B
$2.5B
Q3 24
$9.1B
$2.5B
Q2 24
$8.7B
$2.5B
Q1 24
$8.3B
$2.5B
Debt / Equity
IDA
IDA
LIVN
LIVN
Q4 25
0.93×
0.31×
Q3 25
0.38×
Q2 25
0.38×
Q1 25
0.61×
Q4 24
0.92×
0.47×
Q3 24
0.48×
Q2 24
0.50×
Q1 24
0.51×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDA
IDA
LIVN
LIVN
Operating Cash FlowLast quarter
$137.8M
$82.4M
Free Cash FlowOCF − Capex
$-216.2M
$50.2M
FCF MarginFCF / Revenue
-60.0%
13.9%
Capex IntensityCapex / Revenue
98.3%
8.9%
Cash ConversionOCF / Net Profit
3.16×
2.67×
TTM Free Cash FlowTrailing 4 quarters
$-577.5M
$173.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDA
IDA
LIVN
LIVN
Q4 25
$137.8M
$82.4M
Q3 25
$162.8M
$85.1M
Q2 25
$176.9M
$62.9M
Q1 25
$124.3M
$24.0M
Q4 24
$136.4M
$78.7M
Q3 24
$201.9M
$51.0M
Q2 24
$146.4M
$43.4M
Q1 24
$109.7M
$10.0M
Free Cash Flow
IDA
IDA
LIVN
LIVN
Q4 25
$-216.2M
$50.2M
Q3 25
$-127.9M
$62.2M
Q2 25
$-156.4M
$47.8M
Q1 25
$-77.0M
$13.2M
Q4 24
$-48.9M
$68.3M
Q3 24
$-16.1M
$32.8M
Q2 24
$-199.6M
$31.2M
Q1 24
$-150.3M
$3.6M
FCF Margin
IDA
IDA
LIVN
LIVN
Q4 25
-60.0%
13.9%
Q3 25
-24.3%
17.4%
Q2 25
-34.8%
13.6%
Q1 25
-18.7%
4.2%
Q4 24
-13.0%
21.2%
Q3 24
-3.0%
10.3%
Q2 24
-45.1%
9.8%
Q1 24
-36.0%
1.2%
Capex Intensity
IDA
IDA
LIVN
LIVN
Q4 25
98.3%
8.9%
Q3 25
55.2%
6.4%
Q2 25
74.2%
4.3%
Q1 25
49.0%
3.4%
Q4 24
49.3%
3.2%
Q3 24
41.0%
5.7%
Q2 24
78.2%
3.8%
Q1 24
62.2%
2.2%
Cash Conversion
IDA
IDA
LIVN
LIVN
Q4 25
3.16×
2.67×
Q3 25
1.31×
3.18×
Q2 25
1.85×
2.32×
Q1 25
2.08×
Q4 24
3.60×
1.41×
Q3 24
1.78×
1.55×
Q2 24
1.63×
2.65×
Q1 24
2.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IDA
IDA

Retailrevenues$323.0M90%
Transmissionserviceswheeling$18.6M5%
Energyefficiencyprogramrevenues$11.7M3%
Wholesaleenergysales$10.5M3%
Otherrevenues$9.5M3%

LIVN
LIVN

Other$169.4M47%
Neuromodulation Segment$119.7M33%
Cardiopulmonary Segment$71.8M20%

Related Comparisons